Viracta Therapeutics, Inc. (VIRX)
NASDAQ: VIRX · Real-Time Price · USD
0.200
+0.006 (2.88%)
At close: Nov 4, 2024, 4:00 PM
0.196
-0.005 (-2.25%)
After-hours: Nov 4, 2024, 4:56 PM EST
Viracta Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
7.88M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CareMax | 784.55M |
Ontrak | 12.39M |
Pulmatrix | 11.39M |
Syra Health | 7.74M |
Vaccinex | 356.00K |
VIRX News
- 2 months ago - Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - GlobeNewsWire
- 6 months ago - Viracta Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 6 months ago - Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer - GlobeNewsWire
- 6 months ago - Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 7 months ago - Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma - GlobeNewsWire
- 7 months ago - Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan - GlobeNewsWire